What this is
A 1-page lay summary of the University of Arizona Open-LIFU depression trial (published in Frontiers in Psychiatry, April 2025), written so that a prospective trial participant or an IRB committee member can understand the results in 5 minutes. Includes the standard regulatory disclaimer.
Why this matters
Trial sites repeatedly ask for this kind of summary. Without a community-maintained version, each site writes its own, which means subtle overclaim and inconsistent framing creep in. Standardizing how outcomes are described makes the platform safer to grow.
What to do
- Comment to claim.
- Read the Frontiers paper carefully. Key facts:
- 20-patient cohort
- BDI scores moved from severe depression toward remission within one week
- Over one-third of patients reached remission
- 10 minutes per day via wearable headset
- Weeks 2–3 showed further improvement
- Target was the Default Mode Network
- Write a 1-page summary covering:
- What the trial tested (plain language)
- What was measured
- What was found, with specific numbers
- What the result does and does not mean (especially: research use, not clinical use)
- Where to read more
- Include the short-form regulatory disclaimer verbatim:
Openwater's platform is intended exclusively for research purposes and is not cleared or approved by the FDA for clinical use.
- Submit as a PR to the wiki under "Clinical Resources."
- Request peer review from a clinician before merging.
Definition of done
Skills
- Clinical or scientific writing
- Ability to translate technical results without losing precision
- Comfort with regulatory framing
Scope estimate
4–6 hours.
Helpful starting points
- Frontiers in Psychiatry, April 2025, University of Arizona Open-LIFU paper
- Existing wiki structure: https://wiki.openwater.health
- The short-form disclaimer above
How to claim this issue
- Comment "I'd like to work on this." We'll assign it to you.
- Open a draft PR within ~2 weeks of being assigned.
- Ask any clinical-framing questions on this issue or in our Discord
#contributing channel.
Contact: community@openwater.health
By contributing, you agree to our Contributor License Agreement. (If the CLA isn't yet live when you start, we'll handle it once the flow is up.)
What this is
A 1-page lay summary of the University of Arizona Open-LIFU depression trial (published in Frontiers in Psychiatry, April 2025), written so that a prospective trial participant or an IRB committee member can understand the results in 5 minutes. Includes the standard regulatory disclaimer.
Why this matters
Trial sites repeatedly ask for this kind of summary. Without a community-maintained version, each site writes its own, which means subtle overclaim and inconsistent framing creep in. Standardizing how outcomes are described makes the platform safer to grow.
What to do
Openwater's platform is intended exclusively for research purposes and is not cleared or approved by the FDA for clinical use.
Definition of done
Skills
Scope estimate
4–6 hours.
Helpful starting points
How to claim this issue
#contributingchannel.Contact: community@openwater.health
By contributing, you agree to our Contributor License Agreement. (If the CLA isn't yet live when you start, we'll handle it once the flow is up.)